Market Research Life Sciences Market Research Pharmaceuticals Market Research Vaccines Market Research

Meningococcal Vaccines market research report - Forecast till 2030

Best Price Guarantee Length Publisher Published Date SKU
from $4,950 120 Pages Market Research Future November, 2022 RESFT17489281
Best Price Guarantee
Price from $4,950
Length 120 Pages
Publisher Market Research Future
Published Date November, 2022
SKU RESFT17489281

Meningococcal Vaccines market research report - Forecast till 2030


Market Overview

Meningococcal Vaccines Market size is anticipated to register a healthy CAGR of 7.29% during the review period to reach USD 5.91 billion by the end of 2030. The key factors that drive the worldwide meningococcal antibodies market are the Rising mindfulness and flood in movement immunizations and the expansion in Research and development for antibody innovation. Expanding Consideration in Public Vaccination Projects is supposed to help the development of the meningococcal antibodies market. In any case, the rigid administrative rules and item reviews are expected to hamper market development.

The rising mindfulness about meningococcal antibodies and expanding antimicrobial of a few Neisseria meningitides clonal buildings is prompting a flood in vaccination programs across the globe. For example, a few Neisseria meningitides clonal buildings, especially CC4821 and CC11, keep on showing protection from anti-microbials. Furthermore, expanding episodes of meningococcal infections, likewise, drive the market. Besides, a rising number of voyagers and the incorporation of meningococcal immunization as an obligatory prerequisite for a couple of nations are likewise driving the market.

Market Segmentation
The market segmentation of meningococcal immunizations market is as follows
By Vaccine Type
• Conjugate
• Subcapsular
• Polysaccharide
By Serotype
• MenACWY
• MenB/BC
• MenC
• MenAC
• MenA
By End-user
• Hospitals
• Research & Academic Institutes
• Others

Regional Analysis
North America ruled the worldwide meningococcal immunizations market in 2021. This is because of the presence of central members, a deeply grounded medical services foundation, ideal government drives for immunization improvement and conveyance, and an expansion in the quantity of Research and development associations. Moreover, adolescents, teens, and youthful grown-ups represent 21% of all meningococcal sickness cases in the US and are probably going to emphatically affect the meningococcal immunization market.

The meningococcal antibody market in Europe is being driven by non-benefit associations that give funding to explore projects, medical services proficient preparation, patient data and backing, and request driven by a critical expansion in routine vaccination.

As indicated by the European Place for Illness Counteraction and Control, obtrusive meningococcal sickness (IMD) is the main source of meningitis and septicemia, with an expected 200,000 cases happening every year. The sickness frequently advances quickly with a 8-15% case-casualty proportion. Certain European nations that are planning for a meningococcal immunization program are supporting the meningococcal immunization market.

The Asia-Pacific locale is supposed to show the most elevated CAGR from 2021 to 2030. This is because of the expanded transmission of meningococcal microbes which has brought about a critical expansion in the quantity of clinical projects for the viable improvement of meningococcal immunizations because of capricious events across various age gatherings and nations in the district. This has reinforced the Asia-Pacific meningococcal immunizations market.

Major Players

The prominent players operating in the global meningococcal vaccines market include Pfizer Inc (US), Novartis AG (Switzerland), Incepta Pharmaceuticals Ltd (Bangladesh), BIO-MED (US), Walvax Biotechnology Co., Sanofi S.A.(France), and Serum Institute of India Pvt. Ltd (India), GlaxoSmithKline plc (UK), Merck & Co., Inc (US), Ltd (China), Bio-Manguinhos (Brazil).

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Companies Mentioned

Pfizer Inc (US)
Novartis AG (Switzerland)
Incepta Pharmaceuticals Ltd (Bangladesh)
BIO-MED (US)
Walvax Biotechnology Co.
Sanofi S.A.(France)
and Serum Institute of India Pvt. Ltd (India)
GlaxoSmithKline plc (UK)
Merck & Co.
Inc (US)
Ltd (China)
Bio-Manguinhos (Brazil)

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Executive Summary
2 Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.3 Research Objective
2.4 Market Structure
2.5 Assumptions & Limitations
3 Research Methodology
3.1 Data Mining
3.2 Secondary Research
3.3 Primary Research
3.4 Breakdown Of Primary Respondents
3.5 Forecasting Techniques
3.6 Research Methodology For Market Size Estimation
3.6.1 Bottom-up Approach
3.6.2 Top-down Approach
3.7 Data Triangulation
3.8 Validation
4 Market Dynamics
4.1 Overview
4.2 Drivers
4.2.1 Increasing Awareness And Surge In Travel Vaccine
4.2.2 Increase In R&D For Vaccine Technology
4.3 Restraints
4.3.1 Stringent Regulatory Guidelines And Product Recalls
4.4 Opportunities
4.4.1 Increasing Inclusion In National Immunization Programs
5 Market Factor Analysis
5.1 Value Chain Analysis
5.1.1 R&D
5.1.2 Manufacturing
5.1.3 Distribution & Sales
5.1.4 Post-sales Monitoring
5.2 Porter's Five Forces Model
5.2.1 Threat Of New Entrants
5.2.2 Bargaining Power Of Suppliers
5.2.3 Bargaining Power Of Buyers
5.2.4 Threat Of Substitutes
5.2.5 Intensity Of Rivalry
5.3 Impact Of Covid-19 On The Global Meningococcal Vaccines Market
5.3.1 Overview
5.3.2 Impact On Supply Chain
5.3.3 Impact On Production Of Meningococcal Vaccine
5.3.4 Impact On Key Players
6 Global Meningococcal Vaccines Market, By Vaccine Type
6.1 Overview
6.2 Conjugate
6.3 Subcapsular
6.4 Polysaccharide
7 Global Meningococcal Vaccines Market, By Serotype
7.1 Overview
7.2 Menacwy
7.3 Menb/Bc
7.4 Menc
7.5 Menac
7.6 Mena
8 Global Meningococcal Vaccines Market, By End User
8.1 Overview
8.2 Hospitals
8.3 Research & Academic Institutes
8.4 Others
9 Global Meningococcal Vaccines Market, By Region
9.1 Overview
9.2 North America
9.2.1 Us
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 France
9.3.3 Uk
9.3.4 Italy
9.3.5 Spain
9.3.6 Rest Of Europe
9.4 Asia-pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest Of Asia-pacific
9.5 Rest Of The World
9.5.2 Africa
9.5.3 Latin America
10 Competitive Landscape
10.1 Overview
10.2 Competitive Benchmarking
10.3 Major Growth Strategy In The Global Meningococcal Vaccines Market
10.4 The Leading Player In Terms Of The Number Of Developments In The Global Meningococcal Vaccines Market
10.5 Key Development Analysis
10.6 Key Developments & Growth Strategies
10.6.1 Product Launch/ Product Approval
10.6.2 Partership/Agreement
10.7 Financial Matrix
10.7.1 Sales (Usd Million), 2021
10.7.2 R&D Expenditure (Usd Million), 2021
11 Company Profiles
11.1 Pfizer Inc.
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products/Services Offered
11.1.4 Key Developments
11.1.5 Swot Analysis
11.1.6 Key Strategies
11.2 Novartis Ag
11.2.1 Company Overviews
11.2.2 Financial Overview
11.2.3 Products/Services Offered
11.2.4 Key Developments
11.2.5 Swot Analysis
11.2.6 Key Strategies
11.3 Sanofi S.A.
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products/Services Offered
11.3.4 Key Developments
11.3.5 Swot Analysis
11.3.6 Key Strategies
11.4 Serum Institute Of India Pvt. Ltd.
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products/Services Offered
11.4.4 Key Developments
11.4.5 Swot Analysis
11.4.6 Key Strategies
11.5 Glaxosmithkline Plc.
11.5.1 Company Overview
11.5.2 Financial Overview
11.5.3 Products/Services Offered
11.5.4 Key Developments
11.5.5 Swot Analysis
11.5.6 Key Strategies
11.6 Merck & Co., Inc.
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products Offered
11.6.4 Key Developments
11.6.5 Key Strategies
11.7 Incepta Pharmaceuticals Ltd.
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products/Services Offered
11.7.4 Key Developments
11.7.5 Key Strategies
11.8 Bio-med
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products Offered
11.8.4 Key Developments
11.8.5 Key Strategies
11.9 Walvax Biotechnology Co., Ltd.
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products/Services Offered
11.9.4 Key Developments
11.9.5 Key Strategies
11.10 Bio-manguinhos
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products/Services Offered
11.10.4 Key Developments
11.10.5 Key Strategies
12 Appendix
12.1 References
12.2 Related Reports
List Of Tables
Table 1 List Of Assumptions & Limitations
Table 2 Primary Interviews And Information Gathering Process
Table 3 Global: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 4 Global: Meningococcal Vaccines Market, For Conjugate, By Region, 2018–2030 (Usd Million)
Table 5 Global: Meningococcal Vaccines Market, For Subcapsular, By Region, 2018–2030 (Usd Million)
Table 6 Global: Meningococcal Vaccines Market, For Polysaccharide, By Region, 2018–2030 (Usd Million)
Table 7 Global: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 8 Global: Meningococcal Vaccines Market For Menacwy, By Region, 2018–2030 (Usd Million)
Table 9 Global: Meningococcal Vaccines Market, For Menb/Bc, By Region, 2018–2030 (Usd Million)
Table 10 Global: Meningococcal Vaccines Market, For Menc, By Region, 2018–2030 (Usd Million)
Table 11 Global: Meningococcal Vaccines Market, For Menac, By Region, 2018–2030 (Usd Million)
Table 12 Global: Meningococcal Vaccines Market, For Mena, By Region, 2018–2030 (Usd Million)
Table 13 Global: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 14 Global: Meningococcal Vaccines Market For Hospitals, By Region, 2018–2030 (Usd Million)
Table 15 Global: Meningococcal Vaccines Market, For Research & Academic Institutes, By Region, 2018–2030 (Usd Million)
Table 16 Global: Meningococcal Vaccines Market, For Others, By Region, 2018–2030 (Usd Million)
Table 17 Global: Meningococcal Vaccines Market, By Region, 2018–2030 (Usd Million)
Table 18 North America: Meningococcal Vaccines Market, By Country, 2018–2030 (Usd Million)
Table 19 North America: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 20 North America: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 21 North America: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 22 Us: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 23 Us: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 24 Us: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 25 Canada: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 26 Canada: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 27 Canada: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 28 Europe: Meningococcal Vaccines Market, By Country, 2018–2030 (Usd Million)
Table 29 Europe: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 30 Europe: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 31 Europe: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 32 Germany: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 33 Germany: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 34 Germany: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 35 France: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 36 France: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 37 France: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 38 Uk: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 39 Uk: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 40 Uk: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 41 Italy: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 42 Italy: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 43 Italy: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 44 Spain: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 45 Spain: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 46 Spain: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 47 Rest Of Europe: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 48 Rest Of Europe: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 49 Rest Of Europe: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 50 Asia-pacific: Meningococcal Vaccines Market, By Country, 2018–2030 (Usd Million)
Table 51 Asia-pacific: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 52 Asia-pacific: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 53 Asia-pacific: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 54 Japan: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 55 Japan: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 56 Japan: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 57 China: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 58 China: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 59 China: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 60 India: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 61 India: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 62 India: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 63 Australia: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 64 Australia: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 65 Australia: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 66 South Korea: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 67 South Korea: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 68 South Korea: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 69 Rest Of Asia-pacific: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 70 Rest Of Asia-pacific: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 71 Rest Of Asia-pacific: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 72 Rest Of The World: Meningococcal Vaccines Market, By Region, 2018–2030 (Usd Million)
Table 73 Rest Of The World: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 74 Rest Of The World: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 75 Rest Of The World: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 76 Middle East: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 77 Middle East: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 78 Middle East: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 79 Africa: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 80 Africa: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 81 Africa: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 82 Latin America: Meningococcal Vaccines Market, By Vaccine Type, 2018–2030 (Usd Million)
Table 83 Latin America: Meningococcal Vaccines Market, By Serotype, 2018–2030 (Usd Million)
Table 84 Latin America: Meningococcal Vaccines Market, By End User, 2018–2030 (Usd Million)
Table 85 Major Players In The Global Meningococcal Vaccines Market
Table 86 Most Active Player In The Global Meningococcal Vaccines Market
Table 87 Product Launch/ Product Approval
Table 88 Partership/Agreement
Table 89 Pfizer Inc: Products/Services Offered
Table 90 Pfizer Inc.: Key Developments
Table 91 Novartis Ag: Products/Services Offered
Table 92 Sanofi S.A.: Products/Services Offered
Table 93 Sanofi S.A.: Key Developments
Table 94 Serum Institute Of India Pvt. Ltd.: Products/Services Offered
Table 95 Glaxosmithkline Plc.: Products/Services Offered
Table 96 Merck & Co., Inc.: Products/Services Offered
Table 97 Merck & Co., Inc.: Key Developments
Table 98 Incepta Pharmaceuticals Ltd.: Products/Services Offered
Table 99 Bio-med: Products/Services Offered
Table 100 Walvax Biotechnology Co., Ltd.: Products/Services Offered
Table 101 Bio-manguinhos.: Products/Services Offered
Table 102 Bio-manguinhos.: Key Developments
List Of Figures
Figure 1 Market Synopsis
Figure 2 Global Meningococcal Vaccines Market
Figure 3 Bottom-up And Top-down Approaches
Figure 4 Market Dynamics: Analysis Of The Global Meningococcal Vaccine Market
Figure 5 Driver Impact Analysis
Figure 6 Restraint Impact Analysis
Figure 7 Value Chain Analysis: Global Meningococcal Vaccine Market
Figure 9 Global Meningococcal Vaccines Market, By Vaccine Type, 2021 & 2030 (Usd Million)
Figure 10 Global: Meningococcal Vaccines Market, By Seroyype, 2021 & 2030 (Usd Million)
Figure 11 Global: Meningococcal Vaccines Market, By End User, 2021 & 2030 (Usd Million)
Figure 12 Global: Meningococcal Vaccines Market, By Region 2020 & 2030 (Usd Million)
Figure 13 Global: Meningococcal Vaccines Market Share (%), By Region, 2021
Figure 14 North America: Meningococcal Vaccines Market Share (%), By Country 2021
Figure 15 Europe: Meningococcal Vaccines Market Share (%), By Country 2021
Figure 16 Asia-pacific: Meningococcal Vaccines Market Share (%), By Country 2021
Figure 17 Rest Of The World: Meningococcal Vaccines Market Share (%), By Region 2021
Figure 18 Benchmarking Of Major Competitors
Figure 19 Major Strategy Adopted By Key Players In The Global Meningococcal Vaccines Market
Figure 20 Global Meningococcal Vaccines Market: Competitive Landscape
Figure 21 Sales 2021
Figure 22 R&D Expenditure, 2021
Figure 23 Pfizer Inc: Financial Overview Snapshot
Figure 24 Pfizer Inc: Swot Analysis
Figure 25 Novartis Ag: Financial Overview Snapshot
Figure 26 Novartis Ag: Swot Analysis
Figure 27 Sanofi S.A.: Financial Overview Snapshot
Figure 28 Sanofi S.A.: Swot Analysis
Figure 29 Serum Institute Of India Pvt. Ltd.: Swot Analysis
Figure 30 Glaxosmithkline Plc.: Financial Overview Snapshot
Figure 31 Glaxosmithkline Plc.: Swot Analysis
Figure 32 Merck & Co., Inc.: Financial Overview Snapshot

$4,950
$7,250

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings